A woman reaching for a prescription bottle in a medicine cabinet Results are from an indirect comparison of the FIDELITY and AMBER trials. In patients with moderate to severe chronic kidney disease ...

Please provide your email address to receive an email when new articles are posted on . The National Kidney Foundation launched a public education video series about hyperkalemia for patients with ...

In patients with type 2 diabetes (T2D), the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and sustained use of guideline-recommended renin ...

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

A potassium blood test is used to measure the amount of potassium in your blood. It is part of a panel of blood tests called ...

Please provide your email address to receive an email when new articles are posted on . Overall, 38 patients had hyperkalemia before dialysis, researchers found. A daily intake of greater than 15.33 g ...

A real-world study finds reduced RAASi-related hyperkalemia risk among at-risk patients initiating SGLT2 inhibitors. Sodium glucose cotransporter 2 inhibitor (SGLT2i) use is associated with lower ...

QRS interval widening appears to be highly specific for the diagnosis of hyperkalemia in patients with end-stage kidney disease. ECG changes, in general, have poor sensitivities for hyperkalemia in ...

Hyperkalemia in type 2 diabetes occurred less often with GLP-1 receptor agonists in routine care than dipeptidyl peptidase-4 (DPP-4) inhibitors, a large observational study in Sweden showed. Over a ...

After a hard-fought battle for FDA approval, AstraZeneca has hit another setback on its quest to turn its potassium-reduction drug Lokelma into a blockbuster. AstraZeneca has put the kibosh on two ...